Physician profile
Roger I Rivera
NPI 1730697715
$1,579,679.52
in general payments reported to CMS, 2019-2025
21 companies · $490K in 2025
The $490K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $49K · 2022: $215K · 2023: $370K · 2024: $456K · 2025: $490K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $786K · Travel and Lodging: $372K · Consulting Fee: $74K · Honoraria: $50K · Food and Beverage: $35K · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $785,891.00 |
| Travel and Lodging | $371,902.82 |
| Consulting Fee | $73,520.50 |
| Honoraria | $49,891.00 |
| Food and Beverage | $34,736.25 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $631,580.03 | 2021-2025 | |
| Alkermes, INC. | $414,563.89 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Vanda Pharmaceuticals INC. | $171,518.62 | 2021-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $147,297.29 | 2022-2025 | Auvelity, Symbravo |
| Neurocrine Biosciences, INC. | $83,601.63 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $56,118.22 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $27,252.27 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23,777.75 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $13,348.12 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Idorsia Pharmaceuticals US INC | $8,422.87 | 2023-2024 | Quviviq |
| Janssen Scientific Affairs, LLC | $1,450.00 | 2024 | |
| Janssen Pharmaceuticals, INC | $333.70 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Supernus Pharmaceuticals, INC. | $99.00 | 2023-2024 | Qelbree, Qelbree |
| Csl Behring | $90.71 | 2023 | Hizentra |
| Sunovion Pharmaceuticals INC. | $53.84 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $52.40 | 2021-2023 | Jornay Pm |
| Corium, LLC | $34.56 | 2024 | Azstarys |
| Indivior INC. | $34.47 | 2021-2022 | |
| Eisai INC. | $17.82 | 2021 | |
| Noven Therapeutics, LLC | $17.45 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.